Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where I. Lengvári is active.

Publication


Featured researches published by I. Lengvári.


Brain Research Bulletin | 2003

Examination of sensorimotor performance following middle cerebral artery occlusion in rats

Dora Reglodi; Andrea Tamas; I. Lengvári

Middle cerebral artery occlusion (MCAO) in rats is the most commonly used stroke model. Besides the infarct size, assessment of sensorimotor performance has become increasingly important in neuroprotective drug research. However, contradictions exist about procedures for testing functional outcome following MCAO. The aim of the present study was to evaluate a relatively simple set of neurological tests based on the most commonly used scoring systems, and to describe the functional recovery and correlation with the infarct size in rats sacrificed 2 or 14 days after permanent or transient MCAO. The smaller infarct size of rats with transient occlusion was reflected in the neurological scores only during the first 6h. By day 14, no recovery occurred in postural signs, lateral resistance and spontaneous activity, other signs showed different degrees of recovery. Correlation with the infarct size was found only on certain days in gait disturbance, placing reactions, daily body weight and spontaneous activity. According to our observations, the most commonly used sensorimotor tests provide a useful initial screening of functional deficits, but these tests most probably measure deficits caused by infarction of the core area. It is suggested that these tests should be completed by more refined tests when testing a neuroprotective drug which reduces the infarct size in penumbral areas.


Regulatory Peptides | 2008

PKA-Bad-14-3-3 and Akt-Bad-14-3-3 signaling pathways are involved in the protective effects of PACAP against ischemia/reperfusion-induced cardiomyocyte apoptosis

Boglarka Racz; Balázs Gasz; Ferenc Gallyas; Peter Kiss; Andrea Tamas; Zalán Szántó; Andrea Lubics; I. Lengvári; Gábor K. Tóth; Orsolya Hegyi; Erzsébet Roth; Dora Reglodi

The neuropeptide PACAP (pituitary adenylate cyclase activating polypeptide) and its receptors are widely expressed in the nervous system and various other tissues. PACAP has well-known anti-apoptotic effects in neuronal cell lines. Recent data suggest that PACAP exerts anti-apoptotic effects also in non-neuronal cells. The peptide is present in the cardiovascular system, and has various distinct effects. The aim of the present study was to investigate whether PACAP is protective against in vitro ischemia/reperfusion-induced apoptosis in cardiomyocytes. Cultured cardiomyocytes were exposed to 60 min ischemia followed by 120 min reperfusion. The addition of PACAP1-38 significantly increased cell viability and decreased the ratio of apoptotic cells as measured by MTT test and flow cytometry. PACAP induced the phosphorylation of Akt and protein kinase A. In the present study we also examined the possible involvement of Akt- and protein kinase A-induced phosphorylation and thus inactivation of Bad, a pro-apoptotic member of the Bcl-2 family. It was found that ischemia significantly decreased the levels of phosphorylated Bad, which was counteracted by PACAP. Furthermore, PACAP increased the levels of Bcl-xL and 14-3-3 protein, both of which promote cell survival, and decreased the apoptosis executor caspase-3 cleavage. All effects of PACAP1-38 were inhibited by the PACAP antagonist PACAP6-38. In summary, our results show that PACAP has protective effects against ischemia/reperfusion-induced cardiomyocyte apoptosis and provides new insights into the signaling mechanisms involved in the PACAP-mediated anti-apoptotic effects.


Neuropeptides | 2006

Effect of PACAP in 6-OHDA-induced injury of the substantia nigra in intact young and ovariectomized female rats

Dora Reglödi; Andrea Lubics; Peter Kiss; I. Lengvári; Balázs Gaszner; Gábor K. Tóth; Orsolya Hegyi; Andrea Tamas

Pituitary adenylate cyclase activating polypeptide (PACAP) has neuroprotective effects in various neuronal cultures and in models of brain pathologies in vivo. Among others, it protects dopaminergic neurons in vitro, against 6-OHDA- and rotenone-induced injury. Recently, we have shown that PACAP reduces dopaminergic cell loss and ameliorates behavioral outcome following unilateral 6-OHDA-induced injury of the substantia nigra in male rats. However, after castration, PACAP led only to a slight amelioration of the behavioral symptoms. The aim of the present study was to investigate the degree of neuroprotection exerted by PACAP in female rats, using the same model. It was found that PACAP had no effect on the dopaminergic cell loss in intact female rats, only caused amelioration of certain acute behavioral signs. In contrast, PACAP effectively increased dopaminergic cell survival and decreased behavioral deficits in ovariectomized females. These results indicate that the neuroprotective effect of PACAP in a rat model of Parkinsons disease is gender-specific.


Cell and Tissue Research | 1980

Immunohistochemical Study of the LHRH-Synthesizing Neuron System of Aged Female Rats

Istvan Merchenthaler; I. Lengvári; Judit Horváth; György Sétáló

SummaryThe LHRH-synthesizing neuron system was studied in young proestrous and old female rats, and in aged ovariectomized or reserpine-treated females. The medial preoptic area and septal region of old animals contains more LHRH positive perikarya compared to that of young proestrous rats. Reserpine treatment moderately increases the number of immunostainable LHRH cells, while ovariectomy is ineffective in this respect.


Regulatory Peptides | 2004

Effects of pituitary adenylate cyclase activating polypeptide in a rat model of traumatic brain injury

Orsolya Farkas; Andrea Tamas; Andrea Zsombok; Dóra Reglődi; József Pál; András Büki; I. Lengvári; John T. Povlishock; Tamás Dóczi

Pituitary adenylate cyclase activating polypeptide (PACAP) is a widely distributed neuropeptide that has numerous different actions. Recent studies have shown that PACAP exerts neuroprotective effects not only in vitro but also in vivo, in animal models of global and focal cerebral ischemia, Parkinsons disease and axonal injuries. Traumatic brain injury has an increasing mortality and morbidity and it evokes diffuse axonal injury which further contributes to its damaging effects. The aim of the present study was to examine the possible neuroprotective effect of PACAP in a rat model of diffuse axonal injury induced by impact acceleration. Axonal damage was assessed by immunohistochemistry using an antiserum against beta-amyloid precursor protein, a marker of altered axoplasmic transport considered as key feature in axonal injury. In these experiments, we have established the dose response curves for PACAP administration in traumatic axonal injury, demonstrating that a single post-injury intracerebroventricular injection of 100 microg PACAP significantly reduced the density of damaged, beta-amyloid precursor protein-immunoreactive axons in the corticospinal tract.


Neurotoxicity Research | 2005

Development of neurological reflexes and motor coordination in rats neonatally treated with monosodium glutamate

Peter Kiss; Andrea Tamas; Andrea Lubics; M. Szalai; L. Szalontay; I. Lengvári; Dora Reglödi

Monosodium glutamate (MSG) treatment of neonatal rats causes neuronal degeneration in various brain areas and leads to several neurochemical, endocrinological and behavioral alterations. However, relatively little is known about the development of neurological reflexes and motor coordination of these animals. Therefore, the aim of the present study was to examine the neurobehavioral development of newborn rats treated with MSG. Rats received MSG at postnatal days 1, 3, 5, 7, and 9. Appearance of neural reflexes and reflex performance as well as motor coordination were examined for 5 weeks after birth. The efficacy of MSG treatment was confirmed by histological examination of the arcuate nucleus. We found that MSG treatment delayed the appearance of forelimb placing, forelimb grasp and righting reflexes, besides the retarded somatic development. The treated pups performed surface righting in significantly longer times. Also, worse performance was observed in the foot-fault and rota-rod tests. However, MSG-treated rats reached control levels by the end of the fifth postnatal week. These results show that MSG treatment does not cause permanent alterations in the neurobehavioral development, only delays the appearance of some reflexes and leads to temporary changes in reflex performance and motor coordination signs.


Peptides | 2000

Distribution of PACAP-like immunoreactivity in the nervous system of oligochaeta.

Dora Reglodi; I. Lengvári; Márta Szelier; Sandor Vigh; Akira Arimura

The marked similarity between the primary structures of human, other vertebrate, and the invertebrate tunicate PACAP suggests that PACAP is one of the most highly conserved peptides during the phylogeny of the metazoans. We investigated the distribution of PACAP-like immunoreactivity in the nervous system of three oligochaete (Annelida) worms with immunocytochemistry. The distribution pattern of immunoreactivity was similar in all three species (Lumbricus terrestris, Eisenia fetida, and Lumbricus polyphemus). The cerebral ganglion contains numerous immunoreactive cells and fibers. A few cells and fibers were found in the medial and lateral parts of the subesophageal and ventral cord ganglia. In the peripheral nervous system, immunoreactivity was found in the enteric nervous system, in epidermal sensory cells, and in the clitellum.


Annals of the New York Academy of Sciences | 2006

Comparative Study of the Effects of PACAP in Young, Aging, and Castrated Males in a Rat Model of Parkinson's Disease

Dora Reglödi; Andrea Tamas; I. Lengvári; Gábor K. Tóth; L. Szalontay; Andrea Lubics

Abstract:u2002 We have previously shown that PACAP ameliorates the neurological symptoms and reduces the dopaminergic cell loss in young male rats, in a 6‐hydroxydopamine (6‐OHDA)‐induced lesion of the substantia nigra, a model of Parkinsons disease. In the present study, we compared the effects of PACAP in young, aging, and castrated males. Our results show that PACAP significantly reduced the dopaminergic cell loss in young and aging males. In castrated males, 6‐OHDA did not induce such a severe cell loss, and it was not altered by PACAP. However, PACAP effectively ameliorated behavioral symptoms in all groups, with a degree of recovery depending on age and endocrine status.


Annals of the New York Academy of Sciences | 2006

Effects of Systemic PACAP Treatment in Monosodium Glutamate‐Induced Behavioral Changes and Retinal Degeneration

Peter Kiss; Andrea Tamas; Andrea Lubics; I. Lengvári; M. Szalai; D. Hauser; Z.S. Horvath; Boglarka Racz; Robert Gábriel; Norbert Babai; Gábor K. Tóth; Dora Reglödi

Abstract:u2002 The present article investigated effects of systemic pituitary adenylate cyclase‐activating polypeptide (PACAP) treatment in monosodium glutamate (MSG)‐induced retinal degeneration and neurobehavioral alterations in neonatal rats. It was found that the dose of PACAP that effectively enhances neurobehavioral development in normal rats was able to counteract the retarding effect of MSG on righting, forelimb placing, and grasp reflexes and caused a significant amelioration of the righting and gait reflex performance and motor coordination at 2 weeks of age. In the retina, significant amelioration of neuronal loss in the inner retinal layers was achieved, but it was much less than that observed by local administration.


Annals of the New York Academy of Sciences | 2006

Protective effects of PACAP in excitotoxic striatal lesion

Andrea Tamas; Andrea Lubics; I. Lengvári; Dora Reglödi

Abstract:u2002 The present article investigated the effects of pituitary adenylate cyclase‐activating polypeptide (PACAP) treatment in a quinolinic acid (QA)‐induced unilateral lesion of the striatum, a model of Huntington`s disease (HD). PACAP was given locally, preceding the lesion. Behavioral analysis was performed after 1, 10, and 30 days, when motor activity and asymmetrical signs were evaluated. Three weeks after the treatment, a catalepsy test was performed by haloperidol administration, and finally histological assessment of the striatum was done. Our results show that PACAP treatment attenuated the behavioral deficits and reduced the number of lesioned neurons in the striatum.

Collaboration


Dive into the I. Lengvári's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dora Reglödi

Hungarian Academy of Sciences

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge